The immunotherapy, pembrolizumab, is active against mucosal melanoma tumors

Clinical trials of a new immunotherapy, pembrolizumab, have shown that it prolongs life significantly for patients with bladder cancer and is active against a rare sub-type of melanoma, called mucosal melanoma. The findings were presented in two presentations at the European Cancer Congress 2017.

What feeling does this article give you?
Joy
Disgust
Fear
Anger
Sadness

#hashtags to follow:

European Cancer Congress 2017 [+]   

More #news: